Literature DB >> 16920429

Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices.

Charles E Edmiston1, Michael P Goheen, Gary R Seabrook, Christopher P Johnson, Brian D Lewis, Kellie R Brown, Jonathan B Towne.   

Abstract

BACKGROUND: Infection of intravascular or implanted biomedical devices often involves biofilm-forming staphylococci that are recalcitrant to antimicrobial therapy. The present study investigated the activity of 6 antimicrobial agents against biofilm-forming and non-biofilm-forming strains of staphylococci adherent to the surface of selected biomedical devices.
METHODS: Five clinical staphylococcal strains were selected for study in (1) antibiotic-lock model (ALM) and (b) vascular graft model (Dacron and expanded polytetrafluoroethylene [ePFTE]) devices. Test strains were inoculated for 30 minutes to stabilize microbial adherence and then exposed to antibiotic; the impact on bacterial adherence was assessed at 1, 2, 4, 7, and 10 days.
RESULTS: Regarding ALM, daptomycin and rifampin were effective at eradicating staphylococcal adherence by day 4 (P<.01); linezolid and gentamicin by day 7 (P<.01); vancomycin by day 7; and ceftriaxone failed to eradicate staphylococcal adherence in 4 of 5 strains by day 10. Regarding ePTFE, daptomycin and linezolid eradicated staphylococcal adherence by day 2 (P<.01); rifampin by day 4 (P<.01); vancomycin and gentamicin by day 7 (P<.01); and ceftriaxone failed to eliminate staphylococcal adherence in 3 of 5 strains by day 10. Regarding Dacron, daptomycin and rifampin eradicated adherent strains by day 4 (P<.01); linezolid by day 7 (P<.01), and vancomycin, gentamicin, and ceftriaxone decreased staphylococcal adherence by 90%, 95%, and 78%, respectively, by day 10. COMMENTS: Daptomycin, rifampin, and linezolid demonstrated greater efficacy and speed in eradicating microbial adherence of staphylococcal isolates from selected devices compared with vancomycin, gentamicin, or ceftriaxone (P<.01). Further studies are warranted, however, to validate the clinical efficacy of daptomycin and linezolid in the treatment of biomedical device-associated infections.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16920429     DOI: 10.1016/j.amjsurg.2006.04.009

Source DB:  PubMed          Journal:  Am J Surg        ISSN: 0002-9610            Impact factor:   2.565


  18 in total

1.  In vitro efficacies and resistance profiles of rifampin-based combination regimens for biofilm-embedded methicillin-resistant Staphylococcus aureus.

Authors:  Hung-Jen Tang; Chi-Chung Chen; Kuo-Chen Cheng; Kuan-Ying Wu; Yi-Chung Lin; Chun-Cheng Zhang; Tzu-Chieh Weng; Wen-Liang Yu; Yu-Hsin Chiu; Han-Siong Toh; Shyh-Ren Chiang; Bo An Su; Wen-Chien Ko; Yin-Ching Chuang
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

2.  Daptomycin and tigecycline have broader effective dose ranges than vancomycin as prophylaxis against a Staphylococcus aureus surgical implant infection in mice.

Authors:  Jared A Niska; Jonathan H Shahbazian; Romela Irene Ramos; Jonathan R Pribaz; Fabrizio Billi; Kevin P Francis; Lloyd S Miller
Journal:  Antimicrob Agents Chemother       Date:  2012-02-27       Impact factor: 5.191

3.  Novel fatty acid gentamicin salts as slow-release drug carrier systems for anti-infective protection of vascular biomaterials.

Authors:  A Obermeier; F D Matl; J Schwabe; A Zimmermann; K D Kühn; S Lakemeier; R von Eisenhart-Rothe; A Stemberger; R Burgkart
Journal:  J Mater Sci Mater Med       Date:  2012-04-03       Impact factor: 3.896

4.  Daptomycin antibiotic lock therapy in a rat model of staphylococcal central venous catheter biofilm infections.

Authors:  Andrew D G Van Praagh; Tongchuan Li; Shuxin Zhang; Anu Arya; Liping Chen; Xi-Xian Zhang; Shellie Bertolami; Lawrence I Mortin
Journal:  Antimicrob Agents Chemother       Date:  2011-06-27       Impact factor: 5.191

Review 5.  Use of pharmacodynamic principles to optimise dosage regimens for antibacterial agents in the elderly.

Authors:  Ayman M Noreddin; Virginia Haynes
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

6.  Comparative in vitro activity of bacteriophage endolysin HY-133 against Staphylococcus aureus attached to vascular graft surface.

Authors:  Evgeny A Idelevich; Dennis Knaack; Nyityasmono Tri Nugroho; Georg Peters; Theodosios Bisdas; Sonja Molinaro; Giovanni B Torsello; Karsten Becker; Monika Herten
Journal:  Med Microbiol Immunol       Date:  2019-10-17       Impact factor: 3.402

7.  Antibiotic susceptibility of coagulase-negative staphylococci isolated from very low birth weight babies: comprehensive comparisons of bacteria at different stages of biofilm formation.

Authors:  Yue Qu; Andrew J Daley; Taghrid S Istivan; Suzanne M Garland; Margaret A Deighton
Journal:  Ann Clin Microbiol Antimicrob       Date:  2010-05-27       Impact factor: 3.944

8.  Daptomycin: local application in implant-associated infection and complicated osteomyelitis.

Authors:  Steffen B Rosslenbroich; Michael J Raschke; Carolin Kreis; Nancy Tholema-Hans; Andreas Uekoetter; Rudolf Reichelt; Thomas F Fuchs
Journal:  ScientificWorldJournal       Date:  2012-06-18

9.  Vascular graft infection by Staphylococcus aureus: efficacy of linezolid, teicoplanin and vancomycin systemic prophylaxis protocols in a rat model.

Authors:  E Atahan; N Katrancioglu; Y Oztop; E Tuncer; H Ozer; S Manduz; E Engin; T D Yalta; O Berkan; K Dogan
Journal:  Cardiovasc J Afr       Date:  2009 Mar-Apr       Impact factor: 1.167

10.  Open wounds and rifampicin therapy are associated with rifampicin resistance among staphylococcal vascular graft/endograft infections.

Authors:  Yau Kei Stefan Leung; Bruno Ledergerber; Nadia Eberhard; Carlos A Mestres; Zoran Rancic; Alexander Zimmermann; Reinhard Zbinden; Silvio D Brugger; Annelies S Zinkernagel; Barbara Hasse
Journal:  JAC Antimicrob Resist       Date:  2021-03-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.